Nigeria's WHO-GMP Facility Sets Bar for African Local Manufacturing

Sam Pharmaceutical Limited has commissioned a WHO Good Manufacturing Practice-compliant production facility in Ota, Ogun State, southwestern Nigeria, signalling a measurable shift in how sub-Saharan Africa's largest pharmaceutical market approaches supply chain sovereignty. For QA directors and plant heads operating across the continent, the facility represents a reference point for what domestically financed, regulator-endorsed manufacturing can look like at scale.

The plant's declared output capacity stands at more than 400 million tablets, 50 million capsules, two million bottles of syrup, and one million pouches per month. Financing was structured through a NGN 3 billion term loan from First City Monument Bank (FCMB) in partnership with the Bank of Industry (BoI), alongside more than NGN 3.2 billion in working capital, according to FCMB Managing Director Yemisi Edun. The facility was commissioned on April 8, 2026.

NAFDAC Director-General Mojisola Adeyeye described the facility as evidence of growing compliance with global standards within Nigeria's pharmaceutical sector. That regulatory framing carries weight: NAFDAC's alignment with WHO-GMP benchmarks has historically been a prerequisite for any Nigerian manufacturer seeking to supply public health programmes or pursue export registration in other African markets. Chairman and CEO Amit Bhojwani stated the plant is intended to scale production and strengthen Sam Pharmaceuticals' position in Nigeria's branded generics segment.

Minister of State for Health Adekunle Salako linked the commissioning to the government's broader policy objective of reducing dependence on imported medicines. Ogun State Deputy Governor Noimot Salako-Oyedele cited anticipated job creation and improved access to essential medicines as state-level outcomes. For regulatory affairs leads tracking Africa's evolving GMP landscape, the combination of development finance institution backing and WHO-standard infrastructure at this output scale offers a replicable model worth monitoring.